Cutler Group’s Entera Bio ENTX Stock Holding History

Cutler Group’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,800	Closed	-$7K	–	5851
2021 Q2	$7K	Buy	+10,800	New	+$39.9K	﹤0.01%	4175

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cutler Group's ENTX Position: Q3 2021 in Review

Cutler Group sold out of Entera Bio (ENTX) in Q3 2021, closing a stake of 4,600 shares — an estimated $27K sold.

Cutler Group first reported a position in ENTX in Q2 2021 and held it in 1 quarter. The position peaked at $27K in Q2 2021. 14 funds tracked by Wall St. Rank hold ENTX as of Q3 2021.

Cutler Group reported no remaining Entera Bio position as of Q3 2021 after selling out during the quarter.
Cutler Group sold 4,600 Entera Bio shares in Q3 2021, an estimated $27K.
Cutler Group first reported a position in Entera Bio in Q2 2021 and held it in 1 quarter.
Cutler Group's Entera Bio position peaked at $27K in Q2 2021.
14 funds tracked by Wall St. Rank held Entera Bio as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.